A CYP2D6 interaction is any supplement or co-administered compound that meaningfully changes the activity of the CYP2D6 enzyme, a hepatic protein that metabolizes a large share of psychiatric and pain medications. The enzyme is genetically variable, so the same supplement can produce very different effects across users — a poor metabolizer carries less reserve than an extensive metabolizer when an inhibitor is added on top.
Drug classes the enzyme touches
CYP2D6 is a major pathway for several SSRIs and SNRIs, tricyclic antidepressants, certain antipsychotics, tamoxifen, codeine, tramadol, and some beta-blockers. A supplement that inhibits CYP2D6 can raise blood levels of any of these and shift a previously stable prescription into the toxicity range. This is one reason the platform treats new supplement additions on these prescription classes as gated rather than free.
Inhibitors most often seen in supplement stacks
Strong supplement-side inhibition is less common than with CYP3A4, but it exists. The platform flags pairings with caution when supplements known in published literature to influence CYP2D6 sit beside a substrate prescription — for example berberine with certain antidepressants. The pillar overview at supplement stack mistakes to avoid covers why the safer move is to ask the pharmacist before adding rather than after.
Phenotype variability
Genetic testing reports often classify a user as a poor, intermediate, extensive, or ultra-rapid metabolizer. The platform does not require a phenotype to flag the pair, but a logged phenotype changes the conservatism of the warning. Poor metabolizers carry less reserve, so an inhibitor on top is more likely to push the prescription into the toxicity range. Ultra-rapid metabolizers see the opposite pattern — prodrugs activated by CYP2D6 can produce stronger-than-expected effects from standard doses.
What to do when a flag fires
Hold the new supplement and ask the prescribing clinician or pharmacist whether the pair has been studied for the specific prescription on the user's chart. Do not change the prescription on your own. Where a phenotype has been tested, share the result with the prescriber so the question can be answered against the user's metabolizer status.
Related serotonergic overlap
CYP2D6 inhibition matters for SSRIs and SNRIs both because the prescription level can rise and because some inhibitors carry their own serotonergic profile. See serotonergic interaction for the symptom-escalation rules that apply when both signals overlap on the same user.
Limits of the screen
Published data on supplement-side CYP2D6 effects is thinner than for CYP3A4. A missing flag is not proof of safety; it sometimes only reflects the absence of a specific study. The platform marks low-confidence pairs explicitly so the user can ask a sharper question rather than assume parity with well-studied pairs.
How this appears in Unfair
A CYP2D6 tag on a supplement intersects with the user's prescription profile at add-time. Matched pairs surface a prescriber-question template; logged phenotypes shift the warning tier. Profile changes — a new prescription, a new genetic report — re-run the screen across active stacks.
Clinical safety note
CYP2D6 flags are based on published references and are narrower than a prescriber's chart review. Any new prescription, dose change, or new symptom on a paired stack is a reason to involve a pharmacist or clinician before continuing.